Modifying the schedule and increasing doses of Interleukin-2 administration was necessary to achieve tumor regression.

“we had to alter the schedule we had to give higher and higher doses which mediated toxicity until finally a patient that we treated in 1984 who had widespread melanoma was administered interleukin-2 and was the first patient finally after over 70 other patients to show us a tumor regression”